Senolytic Drug Ruxolitinib Extends Lifespan in Severe Muscular Dystrophy Mice

Duchenne muscular dystrophy (DMD) is a devastating X-linked genetic disease affecting roughly 1 in 3,000 boys, causing progressive muscle wasting, skeletal fragtures, cardiac involvement, and early death. While gene therapies hold long-term promise, current standard-of-care relies on glucocorticoids like deflazacort, which extend ambulation but also increase vertebral fracture risk. This study explores a complementary approach: targeting cellular senescence, a hallmark of aging increasingly linked to chronic disease pathology.

Using the dKO-Hom mouse (lacking both dystrophin and utrophin), which more faithfully replicates severe human DMD than the milder Mdx model, the researchers first confirmed that senescent cells—marked by P21, GLB1 (beta-galactosidase), and FUCA1—accumulate significantly in skeletal and cardiac muscle of 4-week-old dystrophic mice compared to wild-type controls, but not in bone tissue. Critically, double immunofluorescence staining revealed these senescent cells are predominantly macrophages (GLB1+/CD68+, FUCA1+/CD68+, P21+/CD68+), not muscle fibers, satellite cells, or endothelial cells.

Treatment with ruxolitinib (60 mg/kg/day orally for 12 days) produced a striking range of benefits in dKO-Hom mice. It reduced senescent macrophage burden and SASP factors such as macrophage migration inhibitory factor (MIF) in skeletal and cardiac muscle, improved trabecular bone microarchitecture of the lumbar spine L5 vertebra (BV/TV, Tb.N, Tb.Th), and ameliorated muscle and heart histopathology. In the less severe Mdx model, ruxolitinib also increased forelimb grip strength and treadmill running endurance, and reduced serum creatine kinase—a marker of muscle damage. Most strikingly, a single 12-day course of ruxolitinib significantly extended the lifespan of dKO-Hom mice, which typically die very young due to disease severity.

The study further tested fisetin and dasatinib+quercetin (D+Q), other established senolytics, and found they also reduced senescent macrophage counts, though ruxolitinib appeared particularly effective. In a combination arm, co-administration of ruxolitinib with deflazacort (1 mg/kg/day) synergistically improved trabecular bone parameters in both the lumbar spine and proximal tibia, increased osteoblast activity, decreased osteoclast numbers, and further ameliorated skeletal muscle and cardiac pathology compared to deflazacort alone—suggesting that ruxolitinib could complement and potentially offset some bone-damaging effects of glucocorticoid therapy.

These findings reframe DMD pathology in part as a senescence-driven inflammatory disease and position JAK inhibition—already clinically available—as a viable therapeutic strategy. Caveats include the short treatment duration, small animal cohort sizes, the use of mouse models that only partially replicate human DMD, and the absence of long-term safety or efficacy data in humans. Nevertheless, ruxolitinib's existing FDA approval for other indications provides a translational pathway worth pursuing in clinical trials for DMD.